Singular Health boosted its US presence by deploying 500 additional 3DICOM MD® licenses to Provider Network Solutions, securing FDA 510(k) clearance for its cloud platform, and launching education pilots with Miami-Dade schools and Florida International University.
- 500 new 3DICOM MD® licenses deployed to PNS network
- Received US$500,000 payment post-quarter from PNS
- FDA 510(k) clearance for 3DICOM MD® Cloud platform
- Education partnerships with Miami-Dade Public Schools and FIU
- Quarterly operating expenses $1.32 million with $10 million cash
Accelerated US Commercial Deployment with Provider Network Solutions
Singular Health Group (ASX:SHG) ramped up its US commercial rollout in the March quarter by deploying an additional 500 3DICOM MD® licenses to Provider Network Solutions (PNS), bringing the total to 750 licenses across PNS’s primary care network. This expanded footprint supports a growing data set to evaluate clinical outcomes and cost savings from reducing duplicate imaging, a key driver of inefficiency in US healthcare.
PNS estimates duplicate imaging costs around US$35 per member per month across its 4.2 million members. Early results indicate the 3DICOM platform is exceeding expectations, delivering material savings in the 3%–5% range of those costs, according to PNS CEO Dr. Pelayo. This success underpins ongoing discussions for license renewal and expansion, anticipated in late Q3 2026, and fuels joint marketing efforts targeting other US health plans and affiliates nationwide. The company recently confirmed receipt of a US$500,000 payment from PNS following the license deployment milestone, reinforcing the commercial traction of the platform. The deployment builds on momentum from the company's US$500,000 received after deploying 500 new 3DICOM MD® licenses.
Digital Imaging Transition at Life Radiology and Clinical Adoption
Singular Health completed a full go-live of its 3DICOM™ Patient solution at Life Radiology’s Miami clinic during March, replacing outdated CD-ROM image delivery with a cloud-enabled digital platform. The integration with the clinic’s PACS allows seamless retrieval and sharing of CT, MRI, PET, X-ray, and mammography images, accessible directly on patients’ mobile devices in both 2D and 3D formats.
Initial feedback from clinical staff and patients has been very positive, with strong adoption reported. The success at Life Radiology is prompting talks about expanding the digital imaging solution to affiliated clinics in other states, paving a path for broader US clinical rollout. This deployment follows earlier progress documented in the Life Radiology pilot moves to full patient deployment report.
Education Sector Expansion with Miami-Dade and Florida International University
Singular Health broadened its footprint beyond clinical settings by formalising a pilot deployment of its 3DICOM™ EDU platform with Miami-Dade County Public Schools, the third largest US school district. The paid pilot covers five technical colleges and up to 150 students and instructors, providing immersive, clinical-grade 3D medical imaging tools integrated into health science and STEM curricula.
The company also signed a Memorandum of Understanding with Florida International University to pilot 3DICOM across academic, clinical, and research environments. This initiative aims to validate the platform’s utility in medical education and clinical workflows, supporting a strategic pathway into broader US academic and healthcare institutions.
Regulatory Milestone and Interoperability Engagement
The cloud-based, browser-deployed platform removes hardware dependencies and supports faster rollouts across distributed healthcare settings. The company also contributed to the US Department of Health and Human Services Office of the National Coordinator for Health Information Technology’s consultation on diagnostic imaging interoperability, positioning itself as a key player aligned with emerging healthcare standards.
Financial Position and Outlook
Operating expenses for the quarter totalled $1.32 million AUD, with cash at bank standing at $10 million AUD, excluding the post-quarter US$500,000 payment from PNS and an expected R&D tax refund of approximately $471,540 AUD. This provides Singular Health with close to two years of runway to execute its US growth strategy.
While advanced-stage commercial discussions with a major US health plan remain ongoing, timing has extended due to seasonal factors and executive changes. Nonetheless, the company remains confident of securing contracts that will enable scalable national deployments. This sets the stage for broader engagement with payers across the PNS network and joint ventures, potentially unlocking substantial commercial value.
Singular Health’s recent US commercial rollout progressed with 250 licenses deployed and Deployment of 500 additional licences under PNS contract underway illustrate a clear trajectory of growth and regulatory validation that investors will be watching closely.
Bottom Line?
Singular Health’s expanding US deployments, regulatory wins, and education partnerships position it for scalable growth, but finalising key health plan contracts remains the critical next hurdle.
Questions in the middle?
- Will Singular Health convert advanced-stage US health plan talks into binding contracts this year?
- How will pilot results from Miami-Dade schools and FIU influence wider adoption in academic and clinical settings?
- Can the company sustain cost discipline while scaling commercial rollouts and regulatory compliance?